Investigating the translational status of novel nicotinamide N-methyltransferase (NNMT) inhibitors is essential for researchers evaluating metabolic pathways. This comprehensive analytical review addresses the current literature regarding 5-Amino-1MQ human clinical trial data, detailing preclinical findings, cellular mechanisms, and verified quality standards for laboratory research.
Investigating the translational status of novel nicotinamide N-methyltransferase (NNMT) inhibitors is essential for researchers evaluating metabolic pathways. This comprehensive analytical review addresses the current literature regarding 5-Amino-1MQ human clinical trial data, detailing preclinical findings, cellular mechanisms, and verified quality standards for laboratory research.
As of the current peer-reviewed literature, there are no published or completed 5-amino-1mq human clinical trial datasets available in scientific repositories. All empirical evidence regarding 5-amino-1-methylquinolinium originates exclusively from in vitro enzymatic assays, cell culture models, and preclinical rodent studies. Any claims suggesting established human clinical dosing protocols or approved clinical indications are unsupported by published peer-reviewed human data.
While non-clinical investigations have generated interest in the small molecule as a selective membrane-permeable NNMT inhibitor, translational research remains in its early stages. Laboratory investigators analyzing 5-amino-1mq product must rely on preclinical methodologies, in vitro binding kinetics, and animal model protocols when designing experiment parameters.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme responsible for catalyzing the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). In metabolic tissues such as white adipose tissue and liver, elevated NNMT activity acts as a metabolic sink, draining cellular pools of both SAM and nicotinamide necessary for salvage pathways.
5-Amino-1MQ functions as a substrate-competitive, small-molecule inhibitor of NNMT. In vitro enzymatic assays demonstrate that binding 5-Amino-1MQ to the active site of NNMT prevents the methylation of nicotinamide. By blocking this clearance pathway, cell culture studies indicate that researchers can preserve intracellular nicotinamide concentrations, directly driving the salvage synthesis of nicotinamide adenine dinucleotide (NAD+).
Preclinical studies suggest that targeted inhibition of NNMT yields significant downstream shifts in cellular energy flux. In murine models of diet-induced obesity, administration of 5-Amino-1MQ demonstrated a notable increase in intracellular NAD+ levels within white adipocytes. Because NAD+ is a critical coenzyme for mitochondrial complex activity and sirtuin deacetylases (SIRT1/SIRT3), elevating NAD+ availability supports enhanced mitochondrial respiration.
In vitro data indicate that treating cultured adipocytes with NNMT inhibitors increases basal oxygen consumption rates (OCR) and upregulates markers of mitochondrial biogenesis. These biochemical observations form the foundation for current ongoing investigation into how NNMT suppression influences cellular ATP production, oxidative phosphorylation efficiency, and overall metabolic expenditure in laboratory settings.
Research exploring fat-metabolism mechanisms frequently targets adipose tissue NNMT expression. Preclinical rodent studies demonstrate that high-fat diet regimens induce significant upregulation of NNMT in adipocytes, which correlates with reduced intracellular NAD+ levels and altered energy homeostasis.
When exposed to 5-Amino-1MQ in animal models, high-fat-fed mice exhibited a reduction in adipocyte hypertrophy, decreased body mass accumulation without altered caloric intake, and improved systemic glucose tolerance parameters. Laboratory investigations suggest these effects are mediated through increased fatty acid oxidation and altered epigenetics via normalized SAM/SAH ratios. Researchers utilizing compounds from our catalog of research peptides and metabolic modulators frequently examine these specific adipose tissue pathways.
Understanding why a 5-amino-1mq human clinical trial has not yet established validated clinical parameters requires examining the translational gap between animal models and human physiology. Rodent metabolic rates and adipocyte distribution differ significantly from human biology. Furthermore, pharmacokinetics, oral bioavailability, tissue-specific clearance rates, and systemic toxicology profiles of 5-Amino-1MQ have primarily been mapped in murine models.
Before human clinical trials can yield actionable pharmacokinetic (PK) and pharmacodynamic (PD) parameters, extensive formal toxicology, safety profiling, and phase 1 ascending-dose evaluations are necessary. Consequently, academic and private research facilities must treat 5-Amino-1MQ strictly as an investigative tool for in vitro and non-human animal research, avoiding extrapolation to human clinical applications.
When evaluating agents for metabolic and mitochondrial research, scientists frequently compare NNMT inhibitors to direct peptide modulators of cellular bioenergetics. While 5-Amino-1MQ works via small-molecule enzyme inhibition to salvage NAD+, direct mitochondrial-derived peptides act through distinct receptor-mediated or organelle-targeted pathways.
For instance, researchers studying mitochondrial energy expenditure often compare 5-Amino-1MQ against mitochondrial-derived peptides like MOTS-c peptide, which regulates nuclear gene expression during metabolic stress, or cardiolipin-targeted compounds like SS-31, which optimizes electron transport chain efficiency. Additionally, direct coenzyme replenishment strategies explored in NAD+ pathway research represent an alternative experimental axis to enzymatic clearance blockade. Reviewing these distinct mechanisms within the PX1 research portal helps scientists select the appropriate compound class for their specific assay design.
5-Amino-1MQ (5-amino-1-methylquinolinium) possesses a quinolinium-based salt structure with a molecular formula of C10H11N2+ (cation form). It is typically synthesized and supplied as a fluoride or iodide salt to ensure chemical stability and solubility in aqueous research buffers.
The molecular weight of the cationic moiety is approximately 159.21 g/mol. Standard laboratory preparation requires solubilization in dimethyl sulfoxide (DMSO) or sterile aqueous buffers, depending on cell culture assay parameters. Chemical purity and physical state integrity must be rigorously verified before introduction into quantitative enzyme kinetics assays.
Because small-molecule inhibitors can suffer from batch variability or residual synthesis contaminants, rigorous analytical validation is mandatory for reproducible research. PX1 Research subjects every lot of research compounds to dual-stage analytical testing performed by independent, ISO 17025-accredited laboratories.
Purity is quantified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum baseline purity of 98%. Identity and molecular weight are confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS). Lot-specific Certificates of Analysis (COAs) detailing chromatograms and mass spectra are publicly available for every batch supplied, ensuring complete traceability for academic institutions and private laboratories.
For optimal stability, lyophilized or crystalline 5-Amino-1MQ powder must be stored at -20°C in a desiccated container protected from light. Exposure to ambient moisture and heat can accelerate chemical degradation and compromise salt stability.
When reconstituting for cell culture or enzymatic assays, investigators typically dissolve the compound in high-grade DMSO to generate a concentrated stock solution. Stock aliquots should be stored at -80°C to minimize freeze-thaw cycles. Dilutions into final culture media or reaction buffers should be prepared immediately prior to experimental execution. Detailed technical documentation is available via our wholesale lab accounts portal for high-throughput screening applications.
In cell culture models involving sensitive adipocyte or macrophage lines, lipopolysaccharide (LPS) contamination can induce non-specific inflammatory signaling pathways, skewing research data regarding metabolic markers. Therefore, rigorous endotoxin testing is essential.
PX1 Research enforces strict Limulus Amebocyte Lysate (LAL) testing protocols on all lots, ensuring endotoxin levels remain consistently below 0.5 EU/mg. Combined with USA-based manufacturing in GMP-compliant facilities, these quality benchmarks ensure that researchers receive bio-pure compounds suitable for high-precision analytical assays.
Are there any published 5-Amino-1MQ human clinical trials?
No. As of current peer-reviewed literature, there are no published phase 1, 2, or 3 human clinical trials for 5-Amino-1MQ. All existing data are derived from in vitro enzymatic assays and preclinical animal models.
What is the primary cellular target of 5-Amino-1MQ in research?
5-Amino-1MQ acts as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme involved in nicotinamide methylation and energy metabolism regulation.
How does 5-Amino-1MQ influence intracellular NAD+ levels in preclinical models?
By inhibiting NNMT activity, 5-Amino-1MQ prevents the conversion of nicotinamide to 1-methylnicotinamide, preserving nicotinamide for the salvage pathway to increase cellular NAD+ synthesis.
What purity verification standards does PX1 Research provide for 5-Amino-1MQ?
PX1 Research provides lot-specific Certificates of Analysis verified by independent ISO 17025 laboratories, utilizing RP-HPLC (confirming ≥98% purity) and ESI-MS for molecular identity verification.
How should 5-Amino-1MQ be stored in a laboratory setting?
Lyophilized or dry powder forms should be stored desiccated at -20°C. Reconstituted stock solutions in DMSO should be aliquoted and stored at -80°C to prevent degradation from repeated freeze-thaw cycles.
Is 5-Amino-1MQ approved for human clinical use or dietary supplementation?
No. 5-Amino-1MQ is an unapproved investigational chemical compound sold strictly for laboratory research, in vitro assays, and preclinical animal studies. It is not for human or veterinary use.
What solvents are suitable for reconstituting 5-Amino-1MQ for in vitro assays?
5-Amino-1MQ salt forms typically demonstrate high solubility in dimethyl sulfoxide (DMSO) and suitable solubility in aqueous cell culture buffers, depending on the specific salt formulation.
What endotoxin threshold is maintained for PX1 Research compounds?
PX1 Research verifies that endotoxin levels are measured via LAL assays and maintained below 0.5 EU/mg to prevent confounding inflammatory responses in cell culture experiments.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.